The German group Sartorius, a supplier to the pharmaceutical industry, announced on Friday its intention to acquire the Strasbourg biotechnology company Polyplus, an expert in raw materials used in gene therapy, this process consisting in modifying the expression of certain genes in target cells.
Via its French subsidiary, the group has “signed an agreement to acquire Polyplus for approximately 2.4 billion…
